Last updated: October 5, 2026
Phenytoin is an established, off-patent antiseizure medicine with limited API-level exclusivity but meaningful formulation and delivery opportunities. The strongest commercial positions are in safer intravenous presentation, pediatric oral liquids, bioequivalent modified-release capsules, taste-masked products, and manufacturing platforms that reduce precipitation, dosing, and excipient-sensitivity risks.
What is the current commercial and regulatory position of phenytoin?
Phenytoin is marketed in multiple dosage forms, principally as immediate-release capsules, extended-release capsules, oral suspension, chewable tablets, and injectable phenytoin sodium. Fosphenytoin, a water-soluble prodrug, is marketed separately for parenteral administration.
| Product type |
Active form |
Main route |
Commercial status |
Key formulation issue |
| Immediate-release capsule |
Phenytoin free acid or sodium salt |
Oral |
Generic |
Variable absorption and nonlinear pharmacokinetics |
| Extended-release capsule |
Phenytoin sodium |
Oral |
Generic and branded legacy products |
Narrow therapeutic index and formulation-dependent exposure |
| Oral suspension |
Phenytoin sodium |
Oral |
Generic and branded legacy products |
Sedimentation, redispersion, taste, dosing accuracy |
| Chewable tablet |
Phenytoin |
Oral |
Generic |
Taste and solid-dose disintegration |
| Injection |
Phenytoin sodium |
Intravenous or intramuscular |
Generic and branded legacy products |
Alkaline pH, precipitation, vehicle toxicity, administration restrictions |
| Injection |
Fosphenytoin sodium |
Intravenous or intramuscular |
Generic and branded legacy products |
Prodrug conversion, concentration, cost, infusion tolerability |
Phenytoin is a narrow-therapeutic-index drug. Small differences in exposure can produce loss of seizure control or concentration-related toxicity. Its pharmacokinetics are nonlinear because metabolism becomes saturated within the therapeutic range. Dose changes therefore require more caution than for many conventional generic products.
The FDA has approved phenytoin products through abbreviated new drug applications and older full applications. Traditional small-molecule patent exclusivity is no longer the principal barrier to entry. Product differentiation depends on formulation performance, bioequivalence, manufacturing control, regulatory execution, and hospital procurement economics.
What excipients are used in phenytoin products?
The excipient profile varies substantially by dosage form. The most important formulation distinction is between oral products containing phenytoin and injectable products containing the sodium salt.
Oral capsules
Phenytoin and phenytoin sodium capsules commonly use conventional solid-dose excipients such as:
- Lactose or other diluents
- Sugar-based fillers
- Talc
- Magnesium stearate
- Gelatin capsules
- Titanium dioxide and approved capsule colorants
The commercial risk is not usually excipient novelty. It is the effect of excipient selection and manufacturing conditions on dissolution, content uniformity, capsule fill, and exposure.
A manufacturer should control:
- Particle-size distribution of the API.
- Polymorphic or crystalline form.
- Blend uniformity at low drug loads.
- Lubrication time, because over-lubrication can slow dissolution.
- Capsule shell moisture and storage stability.
- Dissolution across multiple pH conditions.
- Batch-to-batch release performance.
Lactose-free or low-lactose products may have commercial value for institutional formularies and selected patient populations. Replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another diluent can change density, compactability, dissolution, and capsule fill weight. The substitution requires product-specific comparative dissolution and bioequivalence work.
Oral suspensions
Commercial phenytoin suspensions generally use a structured aqueous vehicle containing combinations of:
- Sucrose
- Glycerin
- Suspending polymers such as sodium carboxymethylcellulose
- Polysorbate 80 or another wetting agent
- Flavoring agents
- Preservatives
- Purified water
- Small quantities of alcohol in some legacy products
The principal development problem is uniform dosing over the full shelf life. A suspension can pass initial specifications and still create commercial risk if the sediment compacts, the product is difficult to redisperse, or the API adheres to the container.
A robust suspension platform should be evaluated for:
- Sedimentation volume
- Redispersibility after accelerated and long-term storage
- Particle-size growth
- Viscosity at refrigerator and room temperature
- Dose delivery through oral syringes
- Container adsorption
- Preservative effectiveness
- Palatability and aftertaste
- Microbial control
- Compatibility with enteral feeding equipment
A high-value formulation opportunity is a ready-to-administer oral liquid with improved syringe accuracy, low sedimentation, and a pediatric-compatible flavor system. The product should avoid excipient concentrations that create unnecessary sugar, alcohol, or osmotic exposure in children.
Injectable phenytoin sodium
Phenytoin sodium injection is difficult to formulate because the sodium salt requires a strongly alkaline solution. Commercial injection products use a nonaqueous vehicle, commonly propylene glycol with alcohol, together with water and pH adjustment. The label for Dilantin injection identifies approximately 40% propylene glycol, 10% alcohol, and sodium hydroxide in an aqueous vehicle (FDA, 2024a).
The formulation creates several risks:
- Precipitation after dilution or cooling
- Local tissue injury after extravasation
- High osmolality
- Cardiovascular and respiratory toxicity associated with rapid administration
- Vehicle-related tolerability concerns
- Compatibility limitations with dextrose-containing solutions
- Need for controlled infusion rates
- Potential adsorption or particle formation in administration systems
FDA labeling instructs that phenytoin sodium injection should be administered carefully and that normal saline is generally used for dilution and flushing. Dextrose solutions can cause precipitation and are avoided in product handling instructions (FDA, 2024a).
A direct reformulation of phenytoin sodium injection using a lower-risk excipient system would have significant commercial value but also a high regulatory burden. The product would need to demonstrate chemical stability, particulate control, extractables and leachables performance, container-closure integrity, compatibility with infusion devices, and clinical comparability.
Fosphenytoin
Fosphenytoin was developed to address the formulation and administration limitations of phenytoin sodium injection. It is a phosphate prodrug that is water soluble and is converted to phenytoin after administration. Cerebyx labeling identifies tromethamine and hydrochloric acid among the inactive ingredients, with water for injection as the vehicle (FDA, 2024b).
Fosphenytoin has a different excipient strategy from phenytoin sodium:
- Aqueous formulation
- No large propylene glycol vehicle burden
- Reduced precipitation risk under labeled conditions
- Compatibility with intravenous and intramuscular administration
- Conversion-rate and infusion-rate considerations
- Higher cost per treatment in many procurement settings
Its commercial opportunity is strongest in emergency medicine, perioperative seizure management, and institutions seeking an alternative to phenytoin sodium injection. The principal limitation is price competition and the need to demonstrate a clear operational or safety benefit.
How should an excipient strategy address phenytoin’s physicochemical risks?
Phenytoin is a weak acid with low aqueous solubility in its free-acid form. The sodium salt improves aqueous solubility but is sensitive to pH, dilution, temperature, and ionic environment. Formulators should treat salt selection, particle engineering, pH control, and precipitation behavior as an integrated design problem.
Oral solid products
For capsules and tablets, the priority is consistent dissolution rather than solubilization. Useful development tools include:
- Controlled API particle size
- Wetting agents at low concentrations
- Disintegrants selected for rapid dispersion without excessive moisture uptake
- Compression and granulation controls
- Multivariate dissolution testing
- Comparative exposure studies across fed and fasting conditions
The formulation should avoid unnecessary changes to established release behavior. For a narrow-therapeutic-index product, a technically elegant formulation that produces a different exposure profile can create regulatory and litigation risk.
Oral liquids
Suspension systems should use a polymer and surfactant combination that balances viscosity with syringe delivery. Excessive viscosity can reduce dose accuracy and cause caregivers to under-administer the product. Insufficient viscosity can accelerate sedimentation.
Commercially relevant design targets include:
| Attribute |
Preferred commercial target |
| Redispersibility |
Minimal shaking with complete dose recovery |
| Dose delivery |
Accurate through oral syringes and cups |
| Sedimentation |
Slow, non-caking sediment |
| Taste |
Reduced bitterness and metallic aftertaste |
| Preservative system |
Effective at labeled pH and throughout shelf life |
| Packaging |
Child-resistant, low-residue bottle with dosing device |
| Storage |
Room-temperature stability without cold-chain dependence |
Taste masking may use flavor systems, sweeteners, ion-exchange resins, coated particles, or microencapsulation. Any taste-masking technology must preserve dissolution and avoid delayed or erratic phenytoin exposure.
Parenteral products
The most attractive formulation objective is reduction of the organic-solvent burden while maintaining phenytoin concentration and shelf stability. Candidate strategies include:
- Alternative salt or counterion systems
- Complexation
- Cosolvent reduction
- Cyclodextrin-based solubilization
- Lipid or nanodispersion systems
- Lyophilized products for reconstitution
- Lower-concentration ready-to-dilute presentations
Each approach presents a regulatory tradeoff. A complexing agent or cyclodextrin can introduce new safety, renal-clearance, or compatibility questions. A lipid system can create risks involving particle size, sterility, infusion compatibility, and emulsion stability. A lyophilized product may reduce precipitation during storage but shift risk to reconstitution errors and particulate control.
What formulation patents could protect a new phenytoin product?
A new phenytoin product would need protection beyond the old compound patent, which has long expired. Patentable subject matter may include:
- Specific excipient ratios
- Defined particle-size distributions
- Stable supersaturated solutions
- Low-solvent injectable systems
- Suspension systems with controlled sedimentation
- Taste-masked microparticles
- Abuse-deterrent or tamper-resistant packaging
- Oral-syringe dosing systems
- Container-closure combinations that reduce adsorption
- Manufacturing processes that produce a defined polymorph or dissolution profile
- Combination products using phenytoin with another antiseizure agent
- Specific methods of treating seizure types or patient subgroups
The strongest formulation claims generally connect composition to measurable performance. Examples include precipitation limits after dilution, defined dissolution ranges, stability at a specified temperature, or dose recovery after a defined shaking protocol.
Method-of-use patents have less commercial value for a mature generic drug unless they cover a differentiated patient population, dosing regimen, rescue-use protocol, or combination therapy that is clinically and commercially meaningful.
What is the Orange Book and exclusivity status of phenytoin?
Phenytoin does not have meaningful remaining new chemical entity exclusivity. Its branded products have faced generic competition for many years. Current commercial barriers arise primarily from:
- FDA approval requirements
- Narrow-therapeutic-index bioequivalence expectations
- Product-specific formulation performance
- Manufacturing validation
- Hospital purchasing contracts
- Shortages or limited supplier capacity
- Device and packaging requirements
Orange Book-listed patents, if any, must be assessed by product and application number. A legacy branded phenytoin product should not be treated as having a commercially significant patent barrier without a current FDA Orange Book review and corresponding patent-status analysis.
Paragraph IV challenges remain possible against any listed patent, but a generic entrant targeting an old immediate-release product would normally compete on cost and supply reliability rather than on an unexpired compound patent. The more defensible targets are differentiated liquid, injectable, modified-release, or device-linked products.
When does phenytoin lose exclusivity, and what is the generic entry risk?
Phenytoin’s basic market exclusivity has already expired. Generic entry is therefore legally feasible, but launch risk differs by dosage form.
| Product |
Generic entry risk |
Main barrier |
| Immediate-release capsules |
High competition |
Price and supply |
| Extended-release capsules |
Moderate |
Bioequivalence and release consistency |
| Oral suspension |
Moderate |
Palatability, redispersion, dosing accuracy |
| Phenytoin injection |
Moderate |
Precipitation, vehicle toxicity, hospital handling |
| Fosphenytoin injection |
Moderate to high |
Cost, clinical substitution, manufacturing scale |
| Novel low-solvent injection |
Lower initial competition |
Development and regulatory burden |
| Taste-masked pediatric liquid |
Lower initial competition |
Clinical comparability and patent design |
The most credible generic launch scenarios are:
- A standard capsule product with low manufacturing cost.
- A reliable suspension with an integrated oral syringe.
- A hospital-focused phenytoin injection with strong supply continuity.
- A differentiated fosphenytoin product with competitive unit economics.
- A reformulated injectable product that reduces administration restrictions.
Which companies and products compete with phenytoin?
Competition comes from both phenytoin products and alternative antiseizure medicines. The main phenytoin-related commercial products include Dilantin and generic phenytoin products. Cerebyx and generic fosphenytoin compete in the parenteral setting.
Clinical alternatives include levetiracetam, valproate, phenobarbital, lacosamide, and other antiseizure medicines. Levetiracetam has gained hospital use in several acute-care settings because of its operational simplicity and absence of phenytoin’s alkaline, solvent-heavy injectable formulation. This competitive pressure reduces the addressable market for a conventional phenytoin injection but increases the value of a safer, easier-to-administer formulation.
What licensing and business-development opportunities exist?
The most practical licensing opportunities are technology-led rather than compound-led.
Excipient and delivery partnerships
Potential partners include:
- Injectable solubilization technology companies
- Pediatric taste-masking specialists
- Oral-liquid manufacturing platforms
- Prefilled syringe and oral-dosing-device suppliers
- Controlled-release capsule developers
- Hospital compounding and ready-to-administer product manufacturers
A license should be evaluated for freedom to operate around excipient combinations, particle engineering, device claims, and manufacturing processes.
Contract manufacturing
Phenytoin products are suitable for contract manufacturing strategies because the API is mature, demand is established, and formulation complexity varies by product. The highest value lies in manufacturers with:
- Sterile injectable capacity
- High-potency containment
- Suspension filling
- Oral syringe assembly
- Stability-indicating analytical methods
- Experience with narrow-therapeutic-index products
- FDA inspection history for comparable dosage forms
Shortage-driven opportunities
Supply reliability can support premium contracting in hospital markets. A manufacturer with dual API sources, validated alternate excipients, and redundant sterile-fill capacity may capture share without patent exclusivity.
How strong is the patent estate for a new phenytoin formulation?
The legacy phenytoin patent estate is weak as a barrier to standard generic entry. A new formulation patent estate can be moderate or strong if it combines:
- Composition claims
- Process claims
- Device or packaging claims
- Stability claims
- Performance-linked dissolution or precipitation claims
- Method-of-use claims
- Regulatory exclusivity where available
Patent strength depends on claim breadth, prior-art exposure, enablement, obviousness risk, and whether competitors can design around the selected excipient system. Broad claims covering routine use of glycerin, polysorbate, cellulose polymers, propylene glycol, or common capsule fillers are vulnerable. Narrow claims tied to measurable performance and a non-obvious formulation interaction are more defensible.
Key Takeaways
- Phenytoin is an off-patent, narrow-therapeutic-index drug with mature generic competition.
- The main commercial opportunities are formulation-driven, not compound-driven.
- Oral suspensions offer the clearest near-term opportunity through improved redispersion, taste, packaging, and dose accuracy.
- Phenytoin sodium injection has substantial excipient and administration limitations linked to alkaline pH, propylene glycol, alcohol, precipitation, and infusion safety.
- Fosphenytoin provides a competing water-soluble parenteral platform but faces cost pressure.
- A low-solvent or ready-to-administer injectable could command differentiated hospital value if it demonstrates stability, compatibility, and clinical comparability.
- Strong patent protection should focus on defined excipient systems, measurable performance, manufacturing processes, and delivery devices.
- FDA approval, narrow-therapeutic-index bioequivalence, supply reliability, and hospital contracting are more important than legacy compound exclusivity.
FAQs
Can phenytoin be formulated without propylene glycol?
Yes. A conventional phenytoin sodium injection relies on propylene glycol for solubilization, but alternative systems may use prodrug conversion, complexation, lyophilization, or other solubilization technologies. Each approach requires separate stability, compatibility, safety, and regulatory studies.
Which excipient is most important in phenytoin suspension development?
No single excipient controls performance. The interaction between the suspending polymer, wetting agent, particle size, vehicle viscosity, preservative system, and flavor system determines sedimentation, redispersion, dose uniformity, and palatability.
Is phenytoin a good candidate for a pediatric formulation?
Yes, particularly as a taste-masked oral liquid or accurately dosed suspension. The formulation must control bitterness, sedimentation, syringe delivery, sugar and alcohol exposure, and dose uniformity.
Do phenytoin excipients affect bioequivalence?
They can. Excipients may alter wetting, dissolution, gastrointestinal dispersion, absorption rate, and exposure. This risk is more material for a narrow-therapeutic-index drug and for modified-release products.
Is fosphenytoin commercially superior to phenytoin sodium injection?
Fosphenytoin has formulation and administration advantages, including an aqueous prodrug system. Its commercial superiority depends on acquisition cost, hospital protocols, supply availability, and whether purchasers value reduced handling and precipitation risk.
References
-
U.S. Food and Drug Administration. (2024a). Dilantin (phenytoin sodium) injection prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2024b). Cerebyx (fosphenytoin sodium) injection prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2024c). Dilantin Kapseals (extended phenytoin sodium capsules) prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2024d). Phenytoin oral suspension prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2024e). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Anderson, G. D. (2008). Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Therapeutic Drug Monitoring, 30(2), 173-180.
-
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008). Antiepileptic drugs: Best practice guidelines for therapeutic drug monitoring. Epilepsia, 49(7), 1239-1276.
